Page of

Promise and Challenges in Drug Development and Assessment for Cognitive Enhancers 

Promise and Challenges in Drug Development and Assessment for Cognitive Enhancers
Chapter:
Promise and Challenges in Drug Development and Assessment for Cognitive Enhancers
Source:
Cognitive Enhancement in CNS Disorders and Beyond
Author(s):

Jeffrey Cummings

and Kate Zhong

DOI:
10.1093/med/9780190214401.003.0001

Cognitive disturbances are ubiquitous in neurologic and psychiatric disorders. Schizophrenia, depression, developmental disorders, acquired brain disorders (traumatic brain injury and stroke), and neurodegenerative disorders all have cognitive impairment as a manifestation. Cognitive enhancers can improve intellectual function and have been approved for Alzheimer’s dementia, dementia of Parkinson’s disease, and attention deficit hyperactivity disorder. Cognitive enhancers are being developed for other cognitive disorders. There are many advantages for development of symptomatic cognitive enhancers compared to disease-modifying agents. Cognitive enhancers typically modulate transmitter systems. Cross-disease phenotypes such as executive function impairment may represent a development strategy for cognitive enhancing agents. Life cycle management strategies for cognitive enhancers include expanding indications to disorders with related pathophysiology or to different stages of disease severity and development of alternate formulations. Cognitive enhancers can restore essential cognitive capability and are a critical element of optimal care of patients with neurologic and psychiatric disorders.

Sign In

Copyright © 2021. All rights reserved.